Eastern Canadian Colorectal Cancer Consensus Conference 2017.

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John's, Newfoundland and Labrador, 28-30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including ■ identification and management of hereditary gastric and colorectal cancer (crc);■ palliative systemic therapy for metastatic gastric cancer;■ optimum duration of preoperative radiation in rectal cancer-that is, short- compared with long-course radiation;■ management options for peritoneal carcinomatosis in crc;■ implications of tumour location for treatment and prognosis in crc; and■ new molecular markers in crc.

• Publication year

  2018

• Venue

  Current Oncology

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3747/co.25.4083PMID 30111967PMCID PMC6092057
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).

  2020cited by this paper
• Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

  2017cited by this paper
• Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

  2017cited by this paper
• The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

  2017cited by this paper
• Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).

  2017cited by this paper
• Targeted therapy for HER2 driven colorectal cancer.

  2017cited by this paper
• 587PSurvival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients

  2017cited by this paper
• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials †

  2017cited by this paper
• Prognostic Factors of Overall Survival in Upper Urinary Tract Carcinoma: A Systematic Review and Meta-analysis.

  2017cited by this paper
• LBA28_PRKEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

  2017cited by this paper
• Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

  2017cited by this paper
• Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

  2017cited by this paper
• 617OA Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)

  2017cited by this paper
• mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109).

  2017cited by this paper
• Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes

  2017cited by this paper
• Chemotherapy for advanced gastric cancer.

  2017cited by this paper
• 616OPertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)

  2017cited by this paper
• Important molecular genetic markers of colorectal cancer

  2016cited by this paper
• Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

  2016cited by this paper
• Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced gastric cancer.

  2016cited by this paper
• Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.

  2016cited by this paper
• Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

  2016cited by this paper
• Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers

  2015cited by this paper
• Colorectal Cancer Biomarkers: Where Are We Now?

  2015cited by this paper
• Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial

  2015cited by this paper
• Familial gastric cancer: genetic susceptibility, pathology, and implications for management.

  2015cited by this paper
• Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer

  2015cited by this paper
• The Consensus Molecular Subtypes of Colorectal Cancer

  2015cited by this paper
• Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

  2015cited by this paper
• Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

  2015cited by this paper
• Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

  2014cited by this paper
• Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

  2014cited by this paper
• Microbiota organization is a distinct feature of proximal colorectal cancers

  2014cited by this paper
• Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

  2014cited by this paper
• Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.

  2014cited by this paper
• Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre

  2014cited by this paper
• Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

  2014cited by this paper
• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis.

  2014cited by this paper
• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Metastatic Colorectal Cancer: Survival Comparison of Hepatic Resection Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  2014cited by this paper
• HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression

  2014cited by this paper
• Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.

  2013cited by this paper
• FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort

  2013cited by this paper
• The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis

  2013cited by this paper
• A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy

  2013cited by this paper
• Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial

  2013cited by this paper
• Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

  2013cited by this paper
• Preoperative short‐course radiotherapy with delayed surgery in primary rectal cancer

  2012cited by this paper
• Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

  2012cited by this paper
• Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

  2012cited by this paper
• Results of Two Bi-Institutional Prospective Studies Using Intraperitoneal Oxaliplatin With or Without Irinotecan During HIPEC After Cytoreductive Surgery for Colorectal Carcinomatosis

  2011cited by this paper
• Microsatellite instability in colorectal cancer

  2011cited by this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement

  2011cited by this paper
• Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  2011cited by this paper
• Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.

  2011cited by this paper
• Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.

  2010cited by this paper
• Early palliative care for patients with metastatic non-small-cell lung cancer.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Attenuated familial adenomatous polyposis: results from an international collaborative study

  2010cited by this paper
• Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data.

  2010cited by this paper
• Microsatellite instability in colorectal cancer.

  2010cited by this paper
• Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

  2009cited by this paper
• Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity.

  2009cited by this paper
• Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

  2009cited by this paper
• Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

  2009cited by this paper
• Capecitabine and oxaliplatin for advanced esophagogastric cancer.

  2008cited by this paper
• 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer

  2008cited by this paper
• Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study.

  2008cited by this paper
• Extra-Intestinal Manifestations of Familial Adenomatous Polyposis

  2008cited by this paper
• Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

  2008cited by this paper
• Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma.

  2007cited by this paper
• Classification of colorectal cancer based on correlation of clinical, morphological and molecular features

  2007cited by this paper
• Chemotherapy for advanced gastric cancer.

  2007cited by this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.

  2007cited by this paper
• Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

  2006cited by this paper
• Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer

  2006cited by this paper
• Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

  2006cited by this paper
• Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.

  2006cited by this paper
• Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group

  2006cited by this paper
• Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X.

  2005cited by this paper
• Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

  2005cited by this paper
• Interventions to promote breast-feeding: applying the evidence in clinical practice

  2004cited by this paper
• Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

  2004cited by this paper
• Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

  2004cited by this paper
• Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma

  2004cited by this paper
• Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

  2003cited by this paper
• Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH.

  2003cited by this paper
• Hereditary colorectal cancer.

  2003cited by this paper
• Peritoneal carcinomatosis from colorectal cancer

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.

  2001cited by this paper
• Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy

  2001cited by this paper
• Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.

  2001cited by this paper
• The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract

  2001cited by this paper
• Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra‐abdominal cancer

  2000cited by this paper
• Peritoneal carcinomatosis from non‐gynecologic malignancies

  2000cited by this paper

• Assessing neoadjuvant therapy recommendations in 19 national and international guidelines for rectal cancer

  2024cites this paper
• Colorectal cancer treatment guidelines and shared decision making quality and reporting assessment: Systematic review.

  2023cites this paper
• Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada

  2023cites this paper
• Advances in Identification of Susceptibility Gene Defects of Hereditary Colorectal Cancer

  2019cites this paper
• Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.

  2019cites this paper
• 11 Neoadjuvant Chemotherapy for Colorectal Liver Metastases

  2017cites this paper